Any current/future new fundraising through debt or equity?

The management did not explicitly mention any current or future plans for fundraising through debt or equity in the discussed sections. Rajesh Aggarwal highlighted that the company is currently debt-free and has sufficient funds to support growth and investments. Focus is on internal growth, new product launches, backward integration, and R&D to improve margins and scale. There was no indication of plans to raise additional capital externally; instead, growth and expansion are being funded through existing resources and operational cash flows.

Any current/future capex/capital investment/strategic investment?

The company is focusing on expanding its manufacturing capabilities, including increasing the number of reactors from around 150 to roughly 300 for manufacturing technicals and backward integration. New technicals are being introduced; eight technicals are being stopped while six new technicals are planned for the domestic market within 3-4 months. Investment is made in strengthening teams across marketing, strategy, manufacturing, R&D, and the Board by adding senior professionals. Major insecticides manufacturing will move to the Chopanki plant to improve returns. The company is investing in

Future growth expectations in sales/revenue/volumes?

The company expects a decent double-digit growth every year in sales and revenues. Around half a dozen new product launches, including new technicals and biologicals, are planned annually to drive growth. Biological segment growth is expected to be gradual, targeting INR10-15 crores incremental revenue in early years. Focus on launching IP-protected, new generation solutions with less competition to create strong brands. Volume growth is anticipated alongside price pressures, with double-digit volume growth seen in the current year continuing. The Maharatna and Focused Maharatna product catego

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects decent double-digit growth every year in top line and bottom line but refrains from giving exact numbers. Focus on new technologies and product launches, including about half a dozen new products yearly across Herbicide, Insecticide, and Fungicide segments. Earnings growth expected from introduction of OAT product (JV with Nissan) and other R&D-based, IP-protected technicals and formulations. Profitability improvement expected due to backward integration, better product mix (increased Maharatna and Focused Maharatna contribution aiming for 65%-70% share), and reduced

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders in specific numbers or values. However, Rajesh Aggarwal mentioned that the company is positive about growth in both B2B and export segments, with increasing sales targets, particularly with Nissan (targeting INR 400 crores this year and more than INR 500 crores next year). There is mention of starting the procurement for the kharif season, indicating active order buildup for the upcoming sales cycle. The company is implementing digital tools (IL360) to enhance retailer and farmer connectivity, likel

Insecticid.IndiaQ3 FY24Fertilizers & Agrochemicals

Insecticid.India Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹569P/E: 14.0Market Cap: ₹1.8K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

The company expects a decent double-digit growth every year in sales and revenues.
Around half a dozen new product launches, including new technicals and biologicals, are planned annually to drive growth.
Biological segment growth is expected to be gradual, targeting INR10-15 crores incremental revenue in early years.
Focus on launching IP-protected, new generation solutions with less competition to create strong brands.
Volume growth is anticipated alongside price pressures, with double-digit volume growth seen in the current year continuing.
The Maharatna and Focused Maharatna product categories are key growth drivers, with focus to increase their contribution to 65-70% of sales in 2-3 years.
Export and B2B segments are also expected to grow, supported by new registrations and product introductions.
Overall, the company is confident of growing better than the industry with improved top line and bottom line performance in coming years.

Margin guidance

Category 3

The company expects decent double-digit growth every year in top line and bottom line but refrains from giving exact numbers.
Focus on new technologies and product launches, including about half a dozen new products yearly across Herbicide, Insecticide, and Fungicide segments.
Earnings growth expected from introduction of OAT product (JV with Nissan) and other R&D-based, IP-protected technicals and formulations.
Profitability improvement expected due to backward integration, better product mix (increased Maharatna and Focused Maharatna contribution aiming for 65%-70% share), and reduced inventory losses.
Q4 and next fiscal expected to show positive performance with improved profitability visible from Q1.
R&D spend is maintained around INR12-15 crores to support new product development.
Overall, earnings and EPS growth are anticipated over 2-3 years as the company aims to match or beat industry bests.

See what Insecticid.India management said on margin guidance — free account, 30 seconds.

Fundraise plans

The management did not explicitly mention any current or future plans for fundraising through debt or equity in the discussed sections.
Rajesh Aggarwal highlighted that the company is currently debt-free and has sufficient funds to support growth and investments.
Focus is on internal growth, new product launches, backward integration, and R&D to improve margins and scale.
There was no indication of plans to raise additional capital externally; instead, growth and expansion are being funded through existing resources and operational cash flows.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders in specific numbers or values.
However, Rajesh Aggarwal mentioned that the company is positive about growth in both B2B and export segments, with increasing sales targets, particularly with Nissan (targeting INR 400 crores this year and more than INR 500 crores next year).
There is mention of starting the procurement for the kharif season, indicating active order buildup for the upcoming sales cycle.
The company is implementing digital tools (IL360) to enhance retailer and farmer connectivity, likely aiding order capture and management.
Overall, while exact order book figures aren't disclosed, the tone suggests a growing and active order pipeline supported by new product launches and expanding customer engagement.

See what Insecticid.India management said on order book — free account, 30 seconds.

Capex plans

Yes

The company is focusing on expanding its manufacturing capabilities, including increasing the number of reactors from around 150 to roughly 300 for manufacturing technicals and backward integration.
New technicals are being introduced; eight technicals are being stopped while six new technicals are planned for the domestic market within 3-4 months.
Investment is made in strengthening teams across marketing, strategy, manufacturing, R&D, and the Board by adding senior professionals.
Major insecticides manufacturing will move to the Chopanki plant to improve returns.
The company is investing in digitization through a program named IL360 to improve last-mile connectivity with retailers and farmers for better market reach.
R&D spend is expected around INR12 to 15 crores next year, with major investment coming from the Japanese partner.
Plans to launch new patented products and import more from Japan (Nissan partnership), targeting INR500+ crores in sales from Japanese products next year.

Track Insecticid.India — get its next earnings analysis in your feed

How does Insecticid.India rank vs peers in Fertilizers & Agrochemicals?

Pro feature

ThisInsecticid.India

Rev 3Mar 3

See where Insecticid.India sits in Fertilizers & AgrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Insecticid.India rank in Fertilizers & Agrochemicals?

Compare Insecticid.India against every Fertilizers & Agrochemicals company (Q3 FY24) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

What Insecticid.India's management said in earlier quarters

Others in Fertilizers & Agrochemicals this season

Advance Agrolife Ltd (Q4 FY26)
Q4 FY26 total revenue: ₹1,259.07 million, up 40% YoY (Page 24). Key concall takeaways from Advance Agrolife Ltd's Q4 FY26 earnings call — and how it ranks…
Advance Agrolife Ltd (Q1 FY27)
Q1 FY27 revenue from operations: ₹3,304 million, a 96% year-on-year (YoY) increase (Page 23, 25, 22). Key concall takeaways from Advance Agrolife Ltd's Q1 FY27…
Bhagiradha Chemicals & Industries Ltd (Q4 FY26)
158.1 crores . Key concall takeaways from Bhagiradha Chemicals & Industries Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.
Bhagiradha Chemicals & Industries Ltd (Q1 FY27)
195.0 crore . Key concall takeaways from Bhagiradha Chemicals & Industries Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.

Compare:vs Coromandel International Ltd vs Fertilizers & Chemicals Travancore Ltd vs UPL

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Insecticid.India Q3 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Insecticid.India rank in Fertilizers & Agrochemicals?

Continue your research

What Insecticid.India's management said in earlier quarters

Others in Fertilizers & Agrochemicals this season